Table 2.
Demographic and socioeconomic characteristics of analysis population (n = 100)
| Characteristic | n | % |
|---|---|---|
| Age (years), Mean (SD) | 47.71 (11.96) | |
| Sex | ||
| Female | 65 | 65 |
| Race/ethnicitya | ||
| White | 92 | 92 |
| Black or African American (US only) | 3 | 3 |
| Asian (US only) | 3 | 3 |
| Asian or Pacific Islander (CA only) | 1 | 1 |
| American Indian or Alaska Native (US only) | 1 | 1 |
| Hispanic or Latino | 4 | 4 |
| Other | 2 | 2 |
| Country | ||
| Canada | 31 | 31 |
| United States | 69 | 69 |
| Highest level of education completed | ||
| Did not complete high school | 4 | 4 |
| High school diploma or equivalent (GED) | 15 | 15 |
| Some college | 22 | 22 |
| 2-year diploma | 7 | 7 |
| 4-year bachelor’s degree | 28 | 28 |
| Master’s degree | 9 | 9 |
| Doctoral or professional degree | 11 | 11 |
| Other | 4 | 4 |
| Acromegaly duration in years (since diagnosis), Mean (SD) | 10.35 (6.83) | |
| Endocrinologist office location | ||
| Major hospital or university | 66 | 66 |
| Community hospital or clinic | 16 | 16 |
| Private practice | 18 | 18 |
| Current medication/treatmentab | ||
| Somatostatin analogues/SSAs | 64 | 64 |
| Pegvisomant | 32 | 32 |
| Dopamine agonists | 13 | 13 |
| Radiation | 6 | 6 |
| Previous medication/treatmenta | ||
| Somatostatin analogues/SSAs | 45 | 45 |
| Pegvisomant | 27 | 27 |
| Dopamine agonist | 36 | 36 |
| Radiation | 27 | 27 |
aMultiple responses allowed, percentages do not add to 100
bOpen-ended question in which acromegaly specific medications were included